CAR T-cell therapies
iconArrow
Product Candidates
Target
Global Rights
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
CT053*
+
Target:
BCMA
Global Rights:
Global**
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
R/R MM (China)
R/R MM (US, Canada )
R/R MM (IIT)
CT041
+
Target:
Claudin18.2
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/GEJ (China)
GC/PC (US, Canada )
PC (China)
GC/GEJ and PC (IIT)
CT011
+
Target:
GPC3
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (China)
CT032
+
Target:
CD19
Global Rights:
Global**
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
B-NHL (China)
CT0180
+
Target:
GPC3
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (IIT)
CT0181
+
Target:
GPC3
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (IIT)
KJ-C2111(CT0590)
+
Target:
BCMA
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
R/R MM (IIT)
KJ-C1807(CT048)
+
Target:
Claudin18.2
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/GEJ and PC
KJ-C2112
+
Target:
EGFR/EGFRvIII
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Glioblastoma
KJ-C2113
+
Target:
Mesothelin
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Solid tumor
KJ-C2114
+
Target:
Undisclosed
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Solid tumor
mAb
iconArrow
Product Candidates
Target
Global Rights
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
AB011
+
Target:
CLDN18.2
Global Rights:
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/PC (China)

* Denotes our Core Product Candidate;

** Rights in the South Korean market has been licensed out to HK Inno.N (KOSDAQ: 195940);

*** Phase II trials of some indications are pivotal studies;

R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; PC: pancreatic cancer; B-cell non-Hodgkin lymphoma; GEJ: gastroesophageal junction cancer; HCC: hepatocellular carcinoma cancer.